Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0EA3E
|
|||
| Drug Name |
PMID26560530-Compound-26
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
National Cancer Center (S. Korea)
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H18O11
|
|||
| Canonical SMILES |
C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O
|
|||
| InChI |
1S/C22H18O11/c23-10-5-12(24)11-7-18(33-22(31)9-3-15(27)20(30)16(28)4-9)21(32-17(11)6-10)8-1-13(25)19(29)14(26)2-8/h1-6,18,21,23-30H,7H2/t18-,21-/m1/s1
|
|||
| InChIKey |
WMBWREPUVVBILR-WIYYLYMNSA-N
|
|||
| CAS Number |
CAS 989-51-5
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:4806
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tissue transglutaminase (TG2) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Tissue transglutaminase (TG2) | Target's Patent Info | [1] | |
| KEGG Pathway | Huntington's disease | |||
| Pathway Interaction Database | Beta1 integrin cell surface interactions | |||
| Thromboxane A2 receptor signaling | ||||
| Alpha9 beta1 integrin signaling events | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.